In a report released today, Dylan Van Haaften from Stifel Nicolaus maintained a Buy rating on Siemens Healthineers AG (SEMHF – Research Report), with a price target of €60.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Dylan Van Haaften has given his Buy rating due to a combination of factors that suggest a positive outlook for Siemens Healthineers AG. The company’s first-quarter results for fiscal year 2025 surpassed expectations, with a 2% increase in both top-line revenue and adjusted EBIT. This performance was notably driven by strong growth in the imaging segment and a robust free cash flow, which tripled year-over-year.
The order book indicates a promising outlook with an implied 12% growth in equipment, suggesting that the first quarter, initially expected to be the weakest, sets a strong foundation for the rest of the fiscal year. Van Haaften notes that the company’s guidance for fiscal year 2025 is conservative, projecting a 5-6% top-line growth, which could potentially be upgraded later in the year. Furthermore, Siemens Healthineers’ imaging sector, supported by innovations like Photon Counting CT, is expected to maintain momentum, particularly in the US market, despite challenges in China. These elements combined contribute to a favorable investment case, justifying the Buy rating.
In another report released today, Bernstein also maintained a Buy rating on the stock with a €60.00 price target.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEMHF in relation to earlier this year.